| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 579 | 570 | 547 | 530 | 596 | 570 | 552 | 529 | 511 | 510 | 532 | 527 | 532 | 559 | 574 | 586 | 621 |
| Expenses | 527 | 509 | 510 | 481 | 492 | 491 | 481 | 476 | 454 | 451 | 484 | 476 | 465 | 490 | 511 | 534 | 527 |
| EBITDA | 52 | 61 | 37 | 49 | 104 | 80 | 71 | 53 | 57 | 59 | 48 | 51 | 67 | 70 | 64 | 51 | 94 |
| Operating Profit % | 8 % | 10 % | 6 % | 8 % | 16 % | 13 % | 12 % | 9 % | 10 % | 10 % | 8 % | 9 % | 12 % | 11 % | 10 % | 8 % | 15 % |
| Depreciation | 11 | 11 | 11 | 12 | 12 | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 |
| Interest | 2 | 3 | 4 | 5 | 5 | 4 | 4 | 4 | 3 | 2 | 4 | 5 | 4 | 4 | 4 | 4 | 3 |
| Profit Before Tax | 39 | 47 | 22 | 33 | 87 | 61 | 51 | 32 | 37 | 40 | 26 | 28 | 45 | 46 | 41 | 28 | 71 |
| Tax | 9 | 12 | 6 | 9 | 22 | 15 | 13 | 9 | 10 | 10 | 7 | 7 | 13 | 12 | 11 | 7 | 18 |
| Net Profit | 30 | 35 | 16 | 24 | 65 | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 31 | 34 | 30 | 21 | 53 |
| EPS in ₹ | 5.07 | 5.91 | 2.71 | 4.05 | 11.03 | 7.81 | 6.45 | 3.93 | 4.71 | 5.11 | 3.26 | 3.50 | 1.07 | 1.16 | 1.02 | 0.70 | 1.81 |
IOL Chemicals & Pharmaceuticals
IOL Chemicals & Pharmaceuticals
131.68
-4.48
(-3.29%)
Market Cap
3,865.17 Cr
PE Ratio
29.06
Volume
21,01,130.00
Day High - Low
137.50 - 129.69
52W High-Low
139.99 - 67.19
Key Fundamentals
Market Cap
3,865.17 Cr
EPS
4.69
PE Ratio
29.06
PB Ratio
2.22
Book Value
61.27
EBITDA
257.76
Dividend Yield
0.73 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
5.99
Debt to Equity
0.05
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
IOL Chemicals schedules investor meet
May 22, 2026
May 22, 2026IOL Chemicals and Pharmaceuticals Limited has scheduled an investor meet under Regulation 30. The meeting is set to take place on May 29, 2026.
IOL Chemicals Board Comments on Filing DelayMay 20, 2026
May 20, 2026IOL Chemicals and Pharmaceuticals Limited board addressed a one-day delay in submitting the Q3FY26 shareholding pattern under Regulation 31, scheduled for May 20, 2026.
IOL Chemicals & Pharmaceuticals schedules Q4 FY26 analyst/investor conference call for May 22, 2026 at 3:00 PM IST, with senior management participating.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,782.20 | #1 4,27,609.48 | 37.09 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 43.33 | |
6,623.00 | 1,75,819.84 | 68.17 | 10,560.00 | 8.73 | 2,520 | 13.44 | 49.66 | |
4,420.90 | 1,49,623.34 | 68.66 | 13,886.20 | 20.34 | 2,138 | -26.91 | 53.32 | |
1,401.30 | 1,13,194.31 | 29.24 | 27,711.70 | -2.46 | 3,783 | -55.32 | 58.57 | |
1,089.00 | 1,09,578.88 | 21.32 | 26,719.70 | 13.65 | 5,242 | 7.82 | 71.01 | |
1,278.20 | 1,06,684.07 | 25.44 | 33,593.30 | -0.44 | 3,998 | -86.05 | 45.82 | |
2,267.70 | 1,03,643.69 | #1 19.20 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 47.04 | |
2,336.10 | 96,435.39 | 50.16 | 14,277.60 | 12.03 | 1,750 | 31.75 | 47.08 | |
1,462.30 | 84,930.62 | 24.27 | 33,384.70 | 3.21 | 3,376 | 1.99 | 53.78 | |
1,446.80 | 78,106.45 | 86.55 | 6,812.90 | #1 21.03 | 884 | 21.18 | 80.98 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.35 %
Net Income Growth
42.25 %
Cash Flow Change
-38.36 %
ROE
-28.18 %
ROCE
-26.58 %
EBITDA Margin (Avg.)
2.99 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 |
| Fixed Assets | 561 | 752 | 933 | 1,171 | 1,277 |
| Current Assets | 1,081 | 920 | 1,120 | 1,151 | 1,228 |
| Capital Work in Progress | 105 | 90 | 101 | 22 | 94 |
| Investments | 2 | 20 | 20 | 21 | 371 |
| Other Assets | 1,294 | 1,161 | 1,190 | 1,169 | 0 |
| Total Equity & Liabilities | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 |
| Current Liabilities | 513 | 456 | 560 | 610 | 690 |
| Non Current Liabilities | 57 | 58 | 73 | 85 | 98 |
| Total Equity | 1,392 | 1,508 | 1,612 | 1,688 | 1,799 |
| Reserve & Surplus | 1,334 | 1,449 | 1,553 | 1,629 | 1,740 |
| Share Capital | 59 | 59 | 59 | 59 | 59 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -29 | -2 | 6 | 71 |
| Investing Activities | -121 | -120 | -191 | -154 |
| Operating Activities | 93 | 122 | 290 | 179 |
| Financing Activities | -2 | -4 | -93 | 46 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 43.69 % | 43.69 % | 43.69 % | 43.69 % | 43.69 % | 43.69 % | 43.69 % | 43.69 % | 48.19 % | 48.19 % | 48.19 % | 48.19 % | 48.19 % | 48.19 % | 48.19 % | 52.62 % | 52.62 % | 52.62 % | 52.62 % | 52.62 % | 57.48 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.34 % | 2.18 % | 1.41 % | 1.39 % | 1.63 % | 1.49 % | 1.47 % | 2.59 % | 2.25 % | 2.08 % | 1.72 % |
| DIIs | 0.04 % | 0.04 % | 0.36 % | 0.50 % | 0.02 % | 0.02 % | 0.06 % | 0.17 % | 0.02 % | 0.26 % | 0.36 % | 0.37 % | 0.30 % | 0.10 % | 0.08 % | 0.08 % | 0.07 % | 0.02 % | 0.04 % | 0.03 % | 0.02 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 27.30 % | 28.03 % | 29.86 % | 30.15 % | 30.29 % | 31.15 % | 31.15 % | 30.92 % | 30.49 % | 29.28 % | 30.28 % | 30.63 % | 30.98 % | 31.48 % | 31.31 % | 31.23 % | 31.43 % | 30.22 % | 29.97 % | 30.51 % | 31.03 % |
| Others | 28.97 % | 28.24 % | 26.08 % | 25.66 % | 25.99 % | 25.14 % | 25.10 % | 25.23 % | 21.30 % | 22.26 % | 18.84 % | 18.62 % | 19.12 % | 18.84 % | 18.79 % | 14.58 % | 14.40 % | 14.54 % | 15.12 % | 14.76 % | 9.74 % |
| No of Share Holders | 1,09,092 | 1,27,893 | 1,42,022 | 1,45,041 | 1,46,437 | 1,48,907 | 1,45,692 | 1,43,327 | 1,40,177 | 1,26,004 | 1,35,397 | 1,34,235 | 1,30,003 | 1,28,689 | 1,25,979 | 1,26,701 | 1,30,002 | 1,25,040 | 1,36,129 | 1,33,531 | 1,31,550 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 3 | 6 | 4 | 4 | 5 | 0.8 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 2.72 | 8.48 | 7.07 | 5.53 | 8.18 | 1.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Sept 2026 |  Annual General Meeting | NA | 02 Sept 2026 | 110.21 | 136.16 |
| 12 Sept 2021 |  Dividend | ₹ 2.00 /share | 08 Sept 2021 | 142.80 | 110.43 |
| 16 Feb 2022 | Dividend | ₹ 4.00 /share | 15 Feb 2022 | 91.71 | 77.42 |
| 17 Feb 2023 | Dividend | ₹ 4.00 /share | 17 Feb 2023 | 62.59 | 63.30 |
| 16 Feb 2024 | Dividend | ₹ 5.00 /share | 16 Feb 2024 | 87.56 | 82.25 |
| 23 Aug 2024 | Annual General Meeting | NA | 23 Aug 2024 | 74.72 | 93.30 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 79.07 | 74.06 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 72.62 | 73.57 |
| 18 Feb 2025 | Dividend | ₹ 4.00 /share | 18 Feb 2025 | 73.57 | 68.18 |
| 27 Dec 2024 |  Split | 2:10 | 11 Mar 2025 | 82.27 | 82.27 |
| 16 May 2025 | Quarterly Result Announcement | NA | 16 May 2025 | 65.00 | 77.10 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 94.23 | 95.10 |
| 22 Aug 2025 | Annual General Meeting | NA | 22 Aug 2025 | 77.10 | 98.25 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 94.32 | 89.30 |
| 11 Feb 2026 | Quarterly Result Announcement | NA | 11 Feb 2026 | 71.98 | 80.88 |
| 17 Feb 2026 | Dividend | ₹ 1.00 /share | 17 Feb 2026 | 80.88 | 74.81 |
| 20 May 2026 | Quarterly Result Announcement | NA | 20 May 2026 | 105.71 | 110.21 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 21, 2026
May 21, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2026
May 21, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2026
May 20, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2026
May 20, 2026Comments Of Board Of DirectorsMay 20, 2026
May 20, 2026Fixed 39Th Annual General Meeting Of The Company And Book Closure Of Register Of MembersMay 20, 2026
May 20, 2026Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Audited Financial Results For The Quarter And Year Ended 31St March 2026May 20, 2026
May 20, 2026Outcome Of The Board Meeting And Submission Of Audited Financial Results For The Quarter And Year Ended 31St March 2026May 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 18, 2026
May 18, 2026Board Meeting Intimation for Notice Of The Board MeetingMay 13, 2026
May 13, 2026Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 09, 2026
May 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 13, 2026
Apr 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 10, 2026
Apr 10, 2026Disclosure Under Regulation 30 - Participation In Saksham Niveshak CampaignApr 09, 2026
Apr 09, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2026
Apr 04, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 01, 2026
Apr 01, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015Mar 20, 2026
Mar 20, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 20, 2026
Mar 20, 2026Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015Mar 19, 2026
Mar 19, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2026
Mar 19, 2026Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015Mar 19, 2026
Mar 19, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2026
Mar 19, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 18, 2026
Mar 18, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 18, 2026
Mar 18, 2026Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015Mar 18, 2026
Mar 18, 2026Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015Mar 18, 2026
Mar 18, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 07, 2026
Mar 07, 2026EDQM Issued CEP Certificate For METFORMIN HYDROCHLORIDE Process-IIMar 06, 2026
Mar 06, 2026Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 02, 2026
Mar 02, 2026EDQM Issued CEP Certificate For CLOPIDOGREL BESILATEFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Intimation On Communication To Members Regarding Tax Deducted At Source For Interim DividendFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2026
Feb 11, 2026Corporate Action-Board approves DividendFeb 11, 2026
Feb 11, 2026Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2025Feb 11, 2026
Feb 11, 2026Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2025Feb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Feb 04, 2026Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 27, 2026
Jan 27, 2026Board Meeting Intimation for Notice Of The Board MeetingJan 23, 2026
Jan 23, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Motilal Oswal BSE 1000 Index Fund Direct-Growth | 0.01% | 14 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.08% | 0 | 0.00% | 0.01% |
Technical Indicators
RSI(14)
Neutral 72.79
ATR(14)
Volatile 7.46
STOCH(9,6)
Neutral 72.68
STOCH RSI(14)
Neutral 27.70
MACD(12,26)
Bullish 0.75
ADX(14)
Very Strong Trend 57.29
UO(9)
Bearish 54.12
ROC(12)
Uptrend And Accelerating 25.56
WillR(14)
Overbought -10.57
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
